Effects of PTH on osteocyte function

Bone

Volumn 54, Issue 2, 2013, Pages 250-257

  Bellido, Teresita ^a   Saini, Vaibhav ^b   Pajevic, Paola Divieti ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

FGF23; Osteocyte; PTH; PTH receptor; RANKL; Sclerostin

Indexed keywords

CELL PROTEIN; FIBROBLAST GROWTH FACTOR 23; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PROTEIN PPR; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

BONE REMODELING; CALCIUM HOMEOSTASIS; CELL FUNCTION; DOWN REGULATION; GENE DELETION; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; MECHANOTRANSDUCTION; MOLECULAR INTERACTION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PERIOSTEUM; PHOSPHATE METABOLISM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL NICHE; WNT SIGNALING PATHWAY;

ANIMALS; BONE REMODELING; HOMEOSTASIS; HUMANS; OSTEOCYTES; OSTEOGENESIS; PARATHYROID HORMONE; RECEPTORS, PARATHYROID HORMONE;

EID: 84875850665     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.09.016     Document Type: Review

References (75)

1. Aarden E.M., Burger E.H., Nijweide P.J. Function of osteocytes in bone. J Cell Biochem 1994, 55:287-299.
2. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 2011, 26:229-238.
3. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
4. Van Bezooijen R.L., Roelen B.A., Visser A., Wee-Pals L., de Wilt E., Karperien M., et al. Sclerostin ss an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004, 199:805-814.
5. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., et al. Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
6. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a WNT signaling inhibitor. J Biol Chem 2005, 280:26770-26775.
7. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887.
8. Choi H.Y., Dieckmann M., Herz J., Niemeier A. Lrp4, a novel receptor for dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 2009, 4:e7930.
9. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
10. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
11. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
12. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005, 15:928-935.
13. Rhee Y., Allen M.R., Condon K., Lezcano V., Ronda A.C., Galli C., et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling. J Bone Miner Res 2011, 26:1035-1046.
14. Warmington K., Morony S., Sarosi I., Gong G., Stepphens P., Winkler D.G., et al. Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood. J Bone Miner Res 2004, 19:S56.
15. Warmington K., Ominsky M., Bolon B., Cattley R., Stephens P., Lawson A., et al. Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. J Bone Miner Res 2005, 20:S22.
16. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-hora M., Feng J.Q., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011, 17:1231-1234.
17. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
18. Kramer I., Halleux C., Keller H., Pegurri M., Gooi J.H., Weber P.B., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010, 30:3071-3085.
19. Harris S.E., MacDougall M., Horn D., Woodruff K., Zimmer S.N., Rebel V.I., et al. Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defects. Bone 2012, 50:42-53.
20. Yoshiko Y., Wang H., Minamizaki T., Ijuin C., Yamamoto R., Suemune S., et al. Mineralized tissue cells are a principal source of FGF23. Bone 2007, 40:1565-1573.
21. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003, 112:683-692.
22. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, 278:37419-37426.
23. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38:1310-1315.
24. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
25. Rhee Y., Bivi N., Farrow E.G., Lezcano V., Plotkin L.I., White K.E., et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49:636-643.
26. Wang H., Yoshiko Y., Yamamoto R., Minamizaki T., Kozai K., Tanne K., et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008, 23:939-948.
27. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schuler C., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4:e1000154.
28. Heller M., McLean F.C., Bloom W. Cellular transformations in mammalian bones induced by parathyroid extract. Am J Anat 1950, 87:315-345.
29. Cameron D.A., Paschall H.A., Robinson R.A. Changes in the fine structure of bone cells after the administration of parathyroid extract. J Cell Biol 1967, 33:1-14.
30. Fermor B., Skerry T.M. PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res 1995, 10:1935-1943.
31. Woo S., Rooser J., Dusevich V., Kalajzic I., Bonewald L.F. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res 2011, 26:2634-2646.
32. O'Brien C.A., Plotkin L.I., Galli C., Goellner J., Gortazar A.R., Allen M.R., et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008, 3:e2942.
33. Powell W.F., Barry K.J., Tulum I., Kobayashi T., Harris S.E., Bringhurst F., et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol 2011, 209:21-32.
34. Bellido T. Osteocyte apoptosis induce bone resorption and impairs the skeletal response to weightlessness. BoneKEy-Osteovision 2007, 4:252-256.
35. Eriksen E.F. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010, 11:219-227.
36. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40:1434-1446.
37. Kim S.W., Pajevic P.D., Selig M., Barry K.J., Yang J.Y., Shin C.S., Baek W.Y., Kim J.E., Kronenberg H.M. Intermittent PTH administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 2012, 27:2075-2084.
38. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
39. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003, 278:50259-50272.
40. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
41. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007, 22:1957-1967.
42. Gooi J.H., Pompolo S., Karsdal M.A., Kulkarni N.H., Kalajzic I., McAhren S.H., et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 2010, 46(6):1486-1497.
43. Silvestrini G., Ballanti P., Leopizzi M., Sebastiani M., Berni S., Di Vito M., et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007, 38:261-269.
44. Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95:1991-1997.
45. Drake M.T., Srinivasan B., Modder U.I., Peterson J.M., McCready L.K., Riggs B.L., et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95:5056-5062.
46. van Lierop A.H., Witteveen J., Hamdy N., Papapoulos S. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010, 163:833-837.
47. Kramer I., Keller H., Leupin O., Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab 2010, 21:237-244.
48. Tu X., Edwards R., Olivos N., Benson J.D., Galli C., Pellegrini G., et al. Conditional deletion of the parathyroid hormone (PTH) receptor 1 from osteocytes results in decreased bone resorption and a progressive increase in cancellous bone mass. J Bone Miner Res 2011, 25:S16.
49. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
50. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
51. Calvi L.M., Bromberg O., Rhee Y., Weber J.M., Smith J.N., Basil M., et al. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood 2012, 119:2489-2499.
52. Saini V., Barry K., Fulzele K., Feng J., Divieti Pajevic P. PTH/PTHrP (PPR) receptor signaling in osteocytes regulate bone development in temporal manner. J Bone Miner Res 2011, 26(S1):S16.
53. Ito M., Sakai Y., Furumoto M., Segawa H., Haito S., Yamanaka S., et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 2005, 288:E1101-E1109.
54. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146:5358-5364.
55. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
56. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., et al. 1Alpha,25-dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, 289:G1036-G1042.
57. Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
58. Silver J., Kilav R., Sela-Brown A., Naveh-Many T. Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol 2000, 14:626-628.
59. White K.E., Larsson T.E., Econs M.J. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 2006, 27:221-241.
60. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-F889.
61. Kobayashi K., Imanishi Y., Miyauchi A., Onoda N., Kawata T., Tahara H., et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006, 154:93-99.
62. Kawata T., Imanishi Y., Kobayashi K., Miki T., Arnold A., Inaba M., et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007, 18:2683-2688.
63. Brown W.W., Juppner H., Langman C.B., Price H., Farrow E.G., White K.E., et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 2009, 94:17-20.
64. Bonucci E., Gherardi G. Osteocyte ultrastructure in renal osteodystrophy. Virchows Arch A Pathol Anat Histol 1977, 373:213-231.
65. Rodionova N.V., Oganov V.S., Zolotova N.V. Ultrastructural changes in osteocytes in microgravity conditions. Adv Space Res 2002, 30:765-770.
66. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., et al. The WNT co-receptor LRP5 is essential for skeletal mechanotransduction, but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006, 281:23698-23711.
67. Tu X., Rhee Y., Condon K.W., Bivi N., Allen M.R., Dwyer D., et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 2012, 50:209-217.
68. Chow J.W., Fox S., Jagger C.J., Chambers T.J. Role for parathyroid hormone in mechanical responsiveness of rat bone. Am J Physiol 1998, 274:E146-E154.
69. Tu X., Pellegrini G., Galli C., Benson J.D., Condon K.W., Bivi N., et al. PTH receptor 1 expression in osteocytes is indispensable for the anabolic effect of mechanical loading in mice. J Bone Miner Res 2011, 25:S24.
70. Turner R.T., Evans G.L., Lotinun S., Lapke P.D., Iwaniec U.T., Morey-Holton E. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 2007, 22:64-71.
71. Ono N., Nakashima K., Schipani E., Hayata T., Ezura Y., Soma K., et al. Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorption. J Biol Chem 2007, 282:25509-25516.
72. Calvi L.M., Sims N.A., Hunzelman J.L., Knight M.C., Giovannetti A., Saxton J.M., et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001, 107:277-286.
73. LeBlanc A.D., Spector E.R., Evans H.J., Sibonga J.D. Skeletal responses to space flight and the bed rest analog: a review. J Musculoskelet Neuronal Interact 2007, 7:33-47.
74. Qing H., Ardeshirpour L., Pajevic P.D., Dusevich V., Jahn K., Kato S., et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 2012, 27:1018-1029.
75. Van Houten J.N., Wysolmerski J.J. Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology 2003, 144:5521-5529.